Analysis of Lurbinectedin price trends and future reference trends

Lurbinectedin (trade name: Zepzelca) is a new anti-tumor drug mainly used to treat metastatic small cell lung cancer (SCLC). As of 2025, Rubicadin has been launched in many countries and regions around the world, but its prices vary greatly depending on regions, channels and exchange rate fluctuations.

In China, Rubicatin was approved for marketing by the National Medical Products Administration on December 1, 2024, but has not yet been included in the medical insurance list. At present, the price of 4 mg Rubicatin original drug in the domestic market is about 2 more than 10,000 yuan, and patients need to pay the full amount out of their own pocket. Since no generic drugs have yet entered the market, prices are likely to remain stable in the short term.

In the international market, the price of Rubicatin varies greatly. The price of the original drug in the US market is about 9 more than 90,000 yuan per box, while the price in the Singapore market is about 3 more than 10,000 yuan. The price in the Hong Kong market is relatively low, with 4 mg priced at about 2 more than 10,000 yuan per box. These price differences are mainly affected by exchange rate fluctuations, import taxes and fees, and pricing strategies of various countries.

Currently, there are no generic versions of Rubicatin on the market. However, with the increasing demand for this drug in the Chinese market and policy promotion, domestically produced generic drugs may appear in the future, thereby reducing the cost of treatment. Once generic drugs are on the market, prices are expected to drop significantly and the financial burden on patients will be alleviated.

It is expected that with the promotion of Rubicatin in the Chinese market and the increase in the number of patients, the price may decline to a certain extent. If the drug is included in the reimbursement list, patients' out-of-pocket costs will be further reduced. At the same time, the launch of domestic generic drugs will also have a positive impact on prices. Overall, the price of Rubicon is likely to show a gradual downward trend in the coming years.

Reference materials:https://www.drugs.com/